Outcomes with single-agent gilteritinib for relapsed or refractory <i>FLT3</i>-mutant AML after contemporary induction therapy
Jad Othman(King's College London), Richard Dillon(King's College London), Maximillian H. Brodermann(University College London Hospitals NHS Foundation Trust), Nicole Fowler(Royal Cornwall Hospital Trust), Victoria Campbell(Western General Hospital), Paolo Gallipoli(Wellcome/MRC Cambridge Stem Cell Institute), Jenny O’Nions(University College London Hospitals NHS Foundation Trust), Scott Marshall(South Tyneside and Sunderland NHS Foundation Trust), Francesca Hogan(University Hospital of Wales), Rob S. Sellar(Broad Institute), Edward Belsham(Portsmouth Hospitals NHS Trust), Jennifer Vidler(King's College Hospital), Eleana Loizou(Lancashire Teaching Hospitals NHS Foundation Trust), David Taussig(Institute of Cancer Research), Sreetharan Munisamy(East Kent Hospitals University NHS Foundation Trust), Duncan Murray(University Hospitals Coventry and Warwickshire NHS Trust), Mike Dennis(The Christie NHS Foundation Trust), Anjum Khan(Leeds Teaching Hospitals NHS Trust), Kayleigh McCloskey(St Bartholomew's Hospital), Kathryn Fleming(University Hospitals Sussex NHS Foundation Trust), Thomas Taylor(Nottingham University Hospitals NHS Trust), Alexandros Kanellopoulos(Royal Hallamshire Hospital), Justin Loke(Queen Elizabeth Hospital Birmingham), Rui Zhao(Torbay Hospital), Asra Khan(Leeds Teaching Hospitals NHS Trust), Heba Yassin(Queen Mary University of London), Angela Hwang(University College London Hospitals NHS Foundation Trust), Anne‐Louise Latif(Queen Elizabeth University Hospital), Georgina Clarke(James Cook University Hospital), Angela Collins(Norfolk and Norwich University Hospitals NHS Foundation Trust), Faisal Basheer, I. Ben Abdallah(Leeds Teaching Hospitals NHS Trust), Chris Dalley(University Hospital Southampton NHS Foundation Trust), Renuka Palanicawandar(Imperial College Healthcare NHS Trust), Raymond Dang(James Cook University Hospital), Pramila Krishnamurthy(King's College London)
Cited by 10
Related Papers
A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia
|Cell Reports|2016|834
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
|The Lancet Haematology|2016|431
Clonal haematopoiesis and risk of chronic liver disease
|Nature|2023|200